US approves highly anticipated Eli Lilly weight loss drug

The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful -- and lucrative -- new obesity medicines. Zepbound's active ingredient tirzepatide was previously approved under the trade name Mounjaro, a diabetes control drug also made by Eli Lilly.

Related Keywords

Canada ,United States ,United Kingdom ,British ,American ,Joe Nadglowski ,John Sharetts ,Mohit Sodhi ,Eli Lilly ,University Of British Columbia ,Drug Administration ,Journal Of The American Medical Association ,Novo Nordisk ,Obesity Action Coalition ,American Medical Association ,British Columbia ,Weight Loss ,Type 2 Diabetes ,Overweight Patients ,High Cholesterol ,Weight Management ,High Blood Pressure ,Highly Anticipated ,Food And Drug Administration ,